|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Covariates included in the models | Antiplatelets | Antiplatelets + Vitamin K inhibitors | NOACs |
| TIA or IS | Age and gender | 1.51 (1.09-2.09)  p=0.014 | 1.42  (0.93-2.17)  p=0.102 | 1.00  (0.54-1.84)  p=0.997 |
|  | Age, gender, socioeconomic status and CHA2DS2VAc score. | 1.53  (1.08-2.16)  p=0.015 | 1.38  (0.89-2.14)  p=0.153 | 0.98  (0.53-1.80)  p=0.941 |
| CHD | Age and gender | 1.06  (0.83-1.35)  p=0.651 | 1.05  (0.84-1.31)  p=0.678 | 2.07  (1.35-3.19)  p=0.001 |
|  | Age, gender, socioeconomic status and CHA2DS2VAc score. | 1.05  (0.81-1.35)  p=0.717 | 1.06  (0.84-1.32)  p=0.636 | 2.15  (1.34-3.44)  p=0.001 |
| PAD | Age and gender | 1.26  (0.68-2.36)  p=0.461 | 1.33  (0.67-2.64)  p=0.411 | 1.82  (0.68-4.82)  p=0.230 |
|  | Age, gender, socioeconomic status and CHA2DS2VAc score. | 1.13  (0.58-2.20)  p=0.726 | 1.68  (0.83-3.41)  p=0.150 | 2.67  (0.88-8.11)  p=0.082 |
| GI haemorrhage | Age and gender | 1.79  (1.01-3.18)  p=0.047 | 1.46  (0.74-2.91)  p=0.276 | 1.56  (0.63-3.85)  p=0.334 |
|  | Age, gender, socioeconomic status and CHA2DS2VAc score. | 1.77  (0.95-3.29)  p=0.070 | 1.49  (0.70-3.16)  p=0.294 | 1.34  (0.49-3.64)  p=0.565 |

Table 2. Risk (Hazard ratio and 95% Confidence Interval) of outcomes in each treatment category compared to those who took VKAs only during the study period.